Molly Bozic1, Christopher H Goss2,3, Rabindra M Tirouvanziam4, Arthur Baines2, Margaret Kloster2, Liebe Antoine2, Drucy Borowitz5,6, Sarah Jane Schwarzenberg7. 1. Indiana University School of Medicine, Indianapolis, IN. 2. Seattle Children's Research Institute. 3. University of Washington, Seattle, WA. 4. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA. 5. Cystic Fibrosis Foundation, Bethesda, MD. 6. Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY. 7. University of Minnesota Masonic Children's Hospital, Minneapolis, MN.
Abstract
OBJECTIVES: The nutritional status of children with cystic fibrosis (CF) is associated with mortality and morbidity. Intestinal inflammation may contribute to impaired digestion, absorption, and nutrient utilization in patients with CF and oral glutathione may reduce inflammation, promoting improved nutritional status in patients with CF. METHODS: The GROW study was a prospective, multicenter, randomized, placebo-controlled, double-blind, phase II clinical trial in pancreatic insufficient patients with CF between the ages of 2 and 10 years. Patients received reduced glutathione or placebo orally daily for 24 weeks. The primary endpoint was the difference in change in weight-for-age z-scores from baseline through week 24 between treatment groups. Secondary endpoints included other anthropometrics, serum, and fecal inflammatory markers in addition to other clinical outcomes. RESULTS: Fifty-eight participants completed the study. No significant differences were seen between glutathione (n = 30) and placebo (n = 28) groups in the 6-month change in weight-for-age z-score (-0.08; 95% CI: -0.22 to 0.06; P = 0.25); absolute change in weight (kg) (-0.18; 95% CI: -0.55 to 0.20; P = 0.35); or absolute change in BMI kg/m (-0.06; 95% CI: -0.37 to 0.25; P = 0.69). There were no significant differences in other secondary endpoints. Overall, glutathione was safe and well tolerated. CONCLUSIONS: Oral glutathione supplementation did not impact growth or change serum or fecal inflammatory markers in pancreatic insufficient children with CF when compared with placebo.
OBJECTIVES: The nutritional status of children with cystic fibrosis (CF) is associated with mortality and morbidity. Intestinal inflammation may contribute to impaired digestion, absorption, and nutrient utilization in patients with CF and oral glutathione may reduce inflammation, promoting improved nutritional status in patients with CF. METHODS: The GROW study was a prospective, multicenter, randomized, placebo-controlled, double-blind, phase II clinical trial in pancreatic insufficient patients with CF between the ages of 2 and 10 years. Patients received reduced glutathione or placebo orally daily for 24 weeks. The primary endpoint was the difference in change in weight-for-age z-scores from baseline through week 24 between treatment groups. Secondary endpoints included other anthropometrics, serum, and fecal inflammatory markers in addition to other clinical outcomes. RESULTS: Fifty-eight participants completed the study. No significant differences were seen between glutathione (n = 30) and placebo (n = 28) groups in the 6-month change in weight-for-age z-score (-0.08; 95% CI: -0.22 to 0.06; P = 0.25); absolute change in weight (kg) (-0.18; 95% CI: -0.55 to 0.20; P = 0.35); or absolute change in BMI kg/m (-0.06; 95% CI: -0.37 to 0.25; P = 0.69). There were no significant differences in other secondary endpoints. Overall, glutathione was safe and well tolerated. CONCLUSIONS: Oral glutathione supplementation did not impact growth or change serum or fecal inflammatory markers in pancreatic insufficient children with CF when compared with placebo.
Authors: Drucy Borowitz; Peter R Durie; Lane L Clarke; Steven L Werlin; Christopher J Taylor; John Semler; Robert C De Lisle; Peter Lewindon; Steven M Lichtman; Maarten Sinaasappel; Robert D Baker; Susan S Baker; Henkjan J Verkade; Mark E Lowe; Virginia A Stallings; Morteza Janghorbani; Ross Butler; James Heubi Journal: J Pediatr Gastroenterol Nutr Date: 2005-09 Impact factor: 2.839
Authors: Rabindra Tirouvanziam; Tetyana V Obukhanych; Julie Laval; Pavel A Aronov; Robin Libove; Arpita Goswami Banerjee; Karen J Parker; Ruth O'Hara; Leonard A Herzenberg; Leonore A Herzenberg; Antonio Y Hardan Journal: J Autism Dev Disord Date: 2012-05
Authors: Joshua D Chandler; Camilla Margaroli; Hamed Horati; Matthew B Kilgore; Mieke Veltman; H Ken Liu; Alexander J Taurone; Limin Peng; Lokesh Guglani; Karan Uppal; Young-Mi Go; Harm A W M Tiddens; Bob J Scholte; Rabindra Tirouvanziam; Dean P Jones; Hettie M Janssens Journal: Eur Respir J Date: 2018-10-10 Impact factor: 16.671
Authors: Philip H Quanjer; Sanja Stanojevic; Tim J Cole; Xaver Baur; Graham L Hall; Bruce H Culver; Paul L Enright; John L Hankinson; Mary S M Ip; Jinping Zheng; Janet Stocks Journal: Eur Respir J Date: 2012-06-27 Impact factor: 16.671
Authors: C Conrad; J Lymp; V Thompson; C Dunn; Z Davies; B Chatfield; D Nichols; J Clancy; R Vender; M E Egan; L Quittell; P Michelson; V Antony; J Spahr; R C Rubenstein; R B Moss; L A Herzenberg; C H Goss; R Tirouvanziam Journal: J Cyst Fibros Date: 2014-09-13 Impact factor: 5.482
Authors: Jung M Lee; Steven T Leach; Tamarah Katz; Andrew S Day; Adam Jaffe; Chee Y Ooi Journal: Mediators Inflamm Date: 2012-08-21 Impact factor: 4.711